Compare AP & TRDA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | AP | TRDA |
|---|---|---|
| Founded | 1929 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Fluid Controls | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 240.5M | 268.6M |
| IPO Year | 2018 | 2021 |
| Metric | AP | TRDA |
|---|---|---|
| Price | $8.52 | $7.39 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $21.00 |
| AVG Volume (30 Days) | 97.6K | ★ 335.3K |
| Earning Date | 05-12-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.03 | N/A |
| Revenue | ★ $434,166,000.00 | $25,421,000.00 |
| Revenue This Year | N/A | $39.97 |
| Revenue Next Year | N/A | $50.80 |
| P/E Ratio | $293.33 | ★ N/A |
| Revenue Growth | ★ 3.79 | N/A |
| 52 Week Low | $1.75 | $5.02 |
| 52 Week High | $12.81 | $16.45 |
| Indicator | AP | TRDA |
|---|---|---|
| Relative Strength Index (RSI) | 45.60 | 53.67 |
| Support Level | $6.97 | $5.71 |
| Resistance Level | $8.81 | $8.04 |
| Average True Range (ATR) | 0.68 | 0.41 |
| MACD | -0.06 | 0.05 |
| Stochastic Oscillator | 2.20 | 60.00 |
Ampco-Pittsburgh Corp manufactures and sells engineered, high-performance specialty metal products and customized equipment utilized by industry throughout the world. It operates in two business segments, namely the Forged and Cast Engineered Products segment and the Air and Liquid Processing segment. The Forged and Cast Engineered Products segment produces forged hardened steel rolls, cast rolls, and open-die forged products. Forged hardened steel rolls are used in cold rolling mills by producers of steel, aluminum, & other metals. The Air and Liquid Processing segment includes Aerofin, Buffalo Air Handling, & Buffalo Pumps. The company generates a majority of its revenue from the Forged & Cast Engineered Products segment. It has a business presence in the United States & other countries.
Entrada Therapeutics Inc is a clinical-stage biopharmaceutical company. It aims to transform the lives of patients by establishing a new class of medicines that engage intracellular targets that have long been considered inaccessible. The company's Endosomal Escape Vehicle (EEV)-therapeutics are designed to enable the efficient intracellular delivery into a variety of organs and tissues, resulting in an improved therapeutic index and protein-based programs for the potential treatment of neuromuscular and ocular diseases, among others. Its oligonucleotide programs are in development for the potential treatment of people living with Duchenne, which are exon 44, 45, 50, and 51 skipping amenable. It has partnered to develop a clinical-stage program, VX-670, for myotonic dystrophy type 1.